Amgen drops $55M upfront for Rodeo Therapeutics and its prostaglandin blockers

Amgen is adding an arrow to its anti-inflammatory quiver with its buyout of Seattle’s Rodeo Therapeutics. The deal will see just $55 million change hands up front, but another $666 million could come into play if Rodeo’s assets live up to their hype.